The aim of the CRCL International Cancer Symposium is to address fundamental issues of cancer biology from the molecular and biochemical determinants of cancer initiation and dissemination, to the impact of the tumour microenvironment and immunity, and to emphasise synergy between basic, clinical, and translational research. This meeting will also address how tumour cell plasticity contributes to enhanced tumour heterogeneity, sustained metastatic dissemination and escape from conventional and targeted therapies.

    Based on the scientific scope of the meeting, the following thematic sessions are planned:  
    • Session 1: From DNA to protein in cancer
      In cancer, an extreme variety of genetic or epigenetic alterations deregulate a large number of cellular processes favoring tumor development. Among these, gene expression, which proceeds through many sequential steps that are stringently regulated to adapt to cellular and environmental needs at a given time, is often, if not always, deregulated in cancer cells. The tremendous recent technological developments and conceptual advances allow us to hope for achieving an integrated view of gene expression (de)regulation during tumoral processes. From chromatin accessibility to the regulation of protein synthesis, this session will illustrate several key aspects of gene expression plasticity in cancer cells. We will indeed hear about genomic diversity within cancers, genetic or epigenetic determinants in children tumors, mechanisms underlying perturbations of chromatin remodeling complexes or translational regulation across several types of cancers. All the alterations of these gene expression steps are to be taken into account to not only better understand tumor pathology but also identify key actionable targets to design approaches counteracting tumor formation and/or resistance to anti-cancer drugs.
    • Session 2: Cancer immunology
      Cancer Immunology will be undeniably part of the 5th CRCL symposium. Regarding the high craze for the development of novel immunotherapies to treat cancer, the immunology area will be here addressed in a wide range from fundamental to clinic research. The hallmark of this session is also to encourage the effective exchange of ideas between basic cancer immunologists, non-immunologists, and clinical oncologists in order to develop approaches that translate to outcomes. In this session, international leaders in the field will discuss immunomechanisms influencing the tumor growth, computational approaches for network and systems immunology, multiparametric single-cell analysis, cancer immune prevention, and the identification of new targets.
    • Session 3: Cell death and cancer
      Programmed cell death and cancer are unavoidably intertwined: cancer escapes cell death to be able to grow and metastasize, while cancer therapies strive to reinduce cell death to eradicate cancer. Apoptosis, the most well described form of cell death, relies of mitochondrial permeabilization and efficient caspase activation to achieve effective cancer cell killing. In this session, the invited speakers will describe their latest research into how they aim to harness cell death for improving cancer therapy. Starting with molecular basis on mitochondria, caspases and the whole crosstalk between the core apoptotic machinery and other organelles, this session will also include the state-of-the-art therapeutic strategies to improve cell death-centered cancer treatments.
    • Session 4: Plasticity and microenvironment in cancer
      Intra-tumor heterogeneity and intrinsic cancer cell adaptability are key aspects of tumor development by supporting cancer relapse and escape from therapies and have significant clinical implications. It now become obvious that these properties are highly controlled by extrinsic signals provided by the tumor microenvironment which consist in a complex network of macromolecules and different cell types.
    Interaction with both matrix proteins and stromal cells, along with the exposure to soluble factors,
    inflammatory, metabolism, oxidative stresses and biomechanical signals, all contribute to control cancer (stem) cells. This complex multiparametric microenvironment indeed regulates dormancy (quiescence), survival, migration, differentiation and function of cancer cells that in turns remodel their microenvironment, therefore constituting a dynamic system.
    In this session, key players in the field will discuss the role of the dialogue between cancer cells and their microenvironment on stemness, EMT and tumor progression by controlling intra-tumoral heterogeneity in the adaptation of cancer cells.
  • Registration & Information
    26 av Jean Kuntzmann
    38330 Montbonnot - France
    Tel : +33 825 595 525 (0,15€/min*)
    Information desk: Monday to Friday
    From 9:00 to 12:00 and 14:00 to 17:00
    Centre de recherche en cancérologie de Lyon (CRCL)
    UMR Inserm 1052 CNRS 5286 Mixte CLB
    Centre Léon Bérard Cheney D  - 2e étage
    28 rue Laennec
    69373 Lyon Cedex 08 - France 
    Pierre Chaumont
    (*) Prices starting from fixed line incumbent, a surcharge may be applied by operators, counting the second after the first 45 seconds.

    According to France's Personal Data Privacy Act in effect since June 2004, you may send a request in writing to INSIGHT OUTSIDE - 26 avenue Jean Kuntzmann - 38330 Montbonnot / France, or by email webmaster@insight-outside.fr to access your file in order to consult, modify and/or delete your personal information.

    © 2005 - 2024 Insight Outside